Regulation of Blood and Blood products in India, USA and EU
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 2
Abstract
Blood and blood products are precious commodity which gives life to another person. Though we have immense discoveries and invention in science and technology, yet we cannot make blood hence, human blood has no substitute. The availability of safe blood and blood products is essential for diverse modern healthcare services including some surgeries, treatments for cancer, chronic medical conditions, trauma care, organ transplantation, and childbirths that ultimately improve life for millions of patients who are need of transfusion annually. We do not have yet well-defined and stringent regulatory framework for blood products regulation. Frailty may arise from the inability of governments to enforce laws, regulations, and policies and personnel who may not aware or cannot follow quality assurance and/ or good manufacturing practices. While the health sector in developed nation has made outstanding accomplishments in the past few decades. The study sheds on the overview of blood transfusion system in India and other developed nations. There were a mix of methodologies, including literature review (government documents), interviews with key officials in Indian Red Cross Society and analysis of data was used. Results of analysis showed that there are several areas that need to be addressed as it potentially affect the timely availability of safe blood products, which calls for strengthening the planning and monitoring of blood transfusion services.
Authors and Affiliations
Swati Gupta, Harvinder Popli
Keywords
Related Articles
- EP ID EP329342
- DOI 10.22270/ijdra.v6i2.246
- Views 116
- Downloads 0
DRUG REGULATORY PROCEDURES IN TANZANIA: A GLIMPSE
In Tanzania, Tanzania Food and Drugs Authority (TFDA), is a regulatory body responsible for controlling the quality, safety and effectiveness of food, drugs, herbal drugs, cosmetics and medical devices. The Authority has...
Integrating PLCM strategy in Pharmaceutical Emerging Market
All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in...
THE PATH OF PERSONALIZED MEDICINE: REGULATORY PERSPECTIVE
Personalized medicine (PM) has become a topic of great interest because of its potential to improve patient care and optimize therapeutic strategy. The way we understand and treat disease is changing rapidly. The traditi...
FORMULATION AND DEVELOPMENT OF KETOPROFEN BILAYER TABLETS
Aim of present research work was formulation and development of bilayer tablets of Ketoprofen to reduce the side effects of Ketoprofen and to improve the therapeutic benefits and patients’ compliance to treatment. Bi-lay...
Regulatory aspects for Biologic Product licensing in Australia
The TG Act defines biological as product made, from or containing, human cells or human tissues, lives animal organs, cells or tissues, and that is used to treat or prevent disease or injury, Diagnose a condition of a pe...